Gastric Ulceration News and Research

RSS

FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

New Haven Pharmaceuticals, Inc. today announced the availability by prescription of DURLAZA, the first and only 24-hour, extended-release aspirin capsules (162.5mg) approved by the U.S. Food and Drug Administration (FDA) for the secondary prevention of stroke and acute cardiac events, including myocardial infarction (heart attack) in high-risk cardiovascular patients.

7 Jan 2016

New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

New Haven Pharmaceuticals, Inc. today announced new study data that shows the company's FDA-approved drug DURLAZA delivers sustained antiplatelet control for a full 24-hour period in high-risk patients.

10 Nov 2015

Using technology to protect diabetics from foot amputations: an interview with Heleen Kist, HCi Viocare

When people don’t receive the body’s natural signals due to neuropathy, they can unknowingly be exposing their feet to conditions that are known to cause foot ulcers, such as repeated pressure and shear...

4 Jun 2015

Salad herb shows potential gastric anti-ulcer activity

Gastric ulcer is an illness that affects a considerable number of people worldwide. Although the introduction of proton-pump inhibitors to the classic anti-ulcer therapy has revolutionized treatment of peptic ulcers and other gastrointestinal disorders, there is still no complete cure for this disease.

7 May 2009

Potential new ways to treat ulcers

The alarming truth is more than 14.5 million people suffer from ulcers worldwide due to factors such as stress and the use of non-steroidal anti-inflammatory drugs (NSAIDS).

24 Oct 2007